Triple G 20mg mg vial GLP3

GLP3 retatrutide 20mg - characteristics 

Retatrutide 20mg, also referred to as GLP3 reta, is a synthetic amino acid research peptide developed as a triple agonist of GLP-1, GIP and glucagon receptors. The compound is part of a new generation of multi-receptor molecules under study for the regulation of metabolism, glucose homeostasis and energy balance.

A distinctive feature of GLP3 reta (Retatrutide) is its simultaneous activity against three key signaling axes. GLP-1 receptor activation is analyzed in the context of regulation of appetite, delay of gastric emptying and effects on satiety mechanisms. The GIP receptor remains implicated in glucose-dependent modulation of insulin secretion and metabolic response, while the glucagon component is being studied for its effects on energy expenditure and metabolic substrate metabolism. It is this complex receptor profile that makes Retatrutide 20 mg an important study material in analyses of modern metabolic pharmacology.

Where to buy Retatrutide 20mg online availability

GLP3 reta, or retatrutide, is not currently available as a standard drug in pharmacies. The substance is in advanced stages of clinical trials and has not yet been widely approved as a medicinal product for routine use.

The only legal and medically supervised forms of access to retatrutide are the following clinical research programs. Products referred to online as „research peptide” or „research peptide” are not drugs approved for human use, and their quality and composition are not subject to the same standards of control as pharmaceutical products.

From a security perspective GLP3 rheta should only be considered as test substance, rather than as a consumer product.

Metabolism research

Clinical studies have shown that retatrutide 20mg has a very strong effect on weight reduction in obese adults, which was confirmed in randomized placebo-controlled trials conducted for up to 48 weeks.

These studies evaluated several dose levels of retatrutide, applied in a gradual escalation regimen. A clear dose-effect relationship was observed, where higher doses were associated with greater weight loss. In the groups receiving the highest doses, the average weight reduction reached approximately 24-26% of initial weight, one of the highest results recorded in pharmacological obesity treatment studies.

Additional analyses showed that the weight loss was gradual and sustained over the course of therapy, with no abrupt plateau in the final weeks of the study. The weight reduction was mainly in adipose tissue, indicating a beneficial effect of retatrutide on body composition, rather than merely a short-term weight loss resulting from dehydration or loss of lean body mass.

GLP3 Retatrutide 20mg study designs and study observations

GLP3 rheta (retatrutide) does not have an approved dosing regimen for patients, as it remains an investigational substance and all dosing information comes only from phase II and III clinical trial protocols.

In addition to changes in body weight, Retatrutide 20 mg (GLP3 reta) was also analyzed for other metabolic parameters in the study. Improvements in glycemic control, associated with the substance's effect on glucose-dependent insulinotropic response and selected metabolic sensitivity indices, were observed in subjects with type 2 diabetes.

Available body composition analyses indicated that the observed changes were mainly in adipose tissue, which is important in assessing the quality of the metabolic response. The publications also described favorable changes in selected cardiometabolic parameters, including indices related to lipid metabolism and energy metabolism.

Also check out GLP-1 (Orforglipron) capsules 5mg/60caps.

Scientific sources:

1. PubMed - clinical trial of retatrutide in obese subjects (48 weeks)
https://pubmed.ncbi.nlm.nih.gov/37366315/
It confirms the mechanism of action as a GLP-1/GIP/glucagon triagonist and a large reduction in body weight.

2. The New England Journal of Medicine - full publication of the study results
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Describes efficacy (up to ~24% weight loss), safety profile and clinical relevance.

3. PubMed - Phase II study in patients with type 2 diabetes
https://pubmed.ncbi.nlm.nih.gov/37385280/
It confirms improved glycemic control and concomitant weight reduction.

4. PubMed - analysis of retatrutide dosage and tolerability
https://pubmed.ncbi.nlm.nih.gov/38858523/
Describes dose escalation regimens and the dose-effect and dose-effect relationship.

5. NEJM - editorial commentary on triagonists („Triple G”)
https://www.nejm.org/doi/abs/10.1056/NEJMe2307282
Explains the importance of retatrutide as a new generation of obesity therapy.

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.